Maneesh Sud1, Navdeep Tangri1, Melania Pintilie1, Andrew S Levey1, David Naimark2. 1. From the Department of Medicine (M.S., D.N.), the Division of Nephrology, Sunnybrook Health Sciences Centre (D.N.), the Dalla Lana School of Public Health (M.P.), and the Institute of Health Policy Management and Evaluation, Faculty of Medicine (D.N.), University of Toronto, Toronto, Ontario, Canada; the Division of Nephrology, Seven Oaks General Hospital, University of Manitoba, Winnipeg, Manitoba, Canada (N.T.); the Department of Biostatistics, University Health Network, Toronto, Ontario, Canada (M.P.); and the Division of Nephrology, Tufts Medical Centre, Boston, MA (A.S.L.). 2. From the Department of Medicine (M.S., D.N.), the Division of Nephrology, Sunnybrook Health Sciences Centre (D.N.), the Dalla Lana School of Public Health (M.P.), and the Institute of Health Policy Management and Evaluation, Faculty of Medicine (D.N.), University of Toronto, Toronto, Ontario, Canada; the Division of Nephrology, Seven Oaks General Hospital, University of Manitoba, Winnipeg, Manitoba, Canada (N.T.); the Department of Biostatistics, University Health Network, Toronto, Ontario, Canada (M.P.); and the Division of Nephrology, Tufts Medical Centre, Boston, MA (A.S.L.). david.naimark@sunnybrook.ca.
Abstract
BACKGROUND: Patients with chronic kidney disease stages 3 to 5 (glomerular filtration rate <60 mL/min/1.73m(2)) are at increased risk of cardiovascular (CV) disease when compared with patients with less severe chronic kidney disease. How CV events modify the subsequent risk of progression to end-stage-renal disease (ESRD) or all-cause mortality (ACM) before ESRD is not well known. METHODS AND RESULTS: This retrospective cohort study involved 2964 chronic kidney disease subjects referred between January 2001 and December 2008 to the nephrology clinic at Sunnybrook Health Sciences Center, Toronto, Ontario. Interim CV events (heart failure, myocardial infarction, and stroke), ESRD, and ACM were ascertained from administrative data. Over a median follow-up time of 2.76 years (interquartile range, 1.45-4.62), 447 (15%) subjects had a CV event. In the same time period, 318 (11%) developed ESRD, and 446 (15%) experienced ACM before ESRD (156 [5%] from a CV and 290 [10%] from a non-CV-related cause). When analyzed as a time-dependent variable, an interim CV event was associated with a higher risk of subsequent ESRD (hazard ratio, 5.33; 95% confidence interval, 3.74-7.58) and ACM before ESRD (hazard ratio, 4.15, hazard ratio, 3.30-5.23). The hazard ratio for CV-related death versus non-CV-related death before ESRD was 12.38 (95% confidence interval, 8.30-18.45) versus 2.13 (95% confidence interval, 1.57-2.87). CONCLUSIONS: CV events are common in patients with chronic kidney disease stages 3 to 5 and are associated with a substantial increase in the risk of ESRD and ACM before ESRD. Intensive primary and secondary prevention strategies may help attenuate this risk.
BACKGROUND:Patients with chronic kidney disease stages 3 to 5 (glomerular filtration rate <60 mL/min/1.73m(2)) are at increased risk of cardiovascular (CV) disease when compared with patients with less severe chronic kidney disease. How CV events modify the subsequent risk of progression to end-stage-renal disease (ESRD) or all-cause mortality (ACM) before ESRD is not well known. METHODS AND RESULTS: This retrospective cohort study involved 2964 chronic kidney disease subjects referred between January 2001 and December 2008 to the nephrology clinic at Sunnybrook Health Sciences Center, Toronto, Ontario. Interim CV events (heart failure, myocardial infarction, and stroke), ESRD, and ACM were ascertained from administrative data. Over a median follow-up time of 2.76 years (interquartile range, 1.45-4.62), 447 (15%) subjects had a CV event. In the same time period, 318 (11%) developed ESRD, and 446 (15%) experienced ACM before ESRD (156 [5%] from a CV and 290 [10%] from a non-CV-related cause). When analyzed as a time-dependent variable, an interim CV event was associated with a higher risk of subsequent ESRD (hazard ratio, 5.33; 95% confidence interval, 3.74-7.58) and ACM before ESRD (hazard ratio, 4.15, hazard ratio, 3.30-5.23). The hazard ratio for CV-related death versus non-CV-related death before ESRD was 12.38 (95% confidence interval, 8.30-18.45) versus 2.13 (95% confidence interval, 1.57-2.87). CONCLUSIONS: CV events are common in patients with chronic kidney disease stages 3 to 5 and are associated with a substantial increase in the risk of ESRD and ACM before ESRD. Intensive primary and secondary prevention strategies may help attenuate this risk.
Authors: David M J Naimark; Morgan E Grams; Kunihiro Matsushita; Corri Black; Iefke Drion; Caroline S Fox; Lesley A Inker; Areef Ishani; Sun Ha Jee; Akihiko Kitamura; Janice P Lea; Joseph Nally; Carmen Alicia Peralta; Dietrich Rothenbacher; Seungho Ryu; Marcello Tonelli; Hiroshi Yatsuya; Josef Coresh; Ron T Gansevoort; David G Warnock; Mark Woodward; Paul E de Jong Journal: J Am Soc Nephrol Date: 2015-12-11 Impact factor: 10.121
Authors: Junichi Ishigami; Logan T Cowan; Ryan T Demmer; Morgan E Grams; Pamela L Lutsey; Juan-Jesus Carrero; Josef Coresh; Kunihiro Matsushita Journal: J Am Soc Nephrol Date: 2020-01-09 Impact factor: 10.121
Authors: Luigi Tarantini; Giulia Barbati; Giovanni Cioffi; Finlay Aleck McAlister; Justin Adrian Ezekowitz; Carmine Mazzone; Giorgio Faganello; Giulia Russo; Enrico Franceschini Grisolia; Andrea Di Lenarda Journal: Intern Emerg Med Date: 2015-06-30 Impact factor: 3.397
Authors: Joerg C Schefold; Gerasimos Filippatos; Gerd Hasenfuss; Stefan D Anker; Stephan von Haehling Journal: Nat Rev Nephrol Date: 2016-08-30 Impact factor: 28.314
Authors: Charlotte Gimpel; Bernd A Jung; Sabine Jung; Johannes Brado; Daniel Schwendinger; Barbara Burkhardt; Martin Pohl; Katja E Odening; Julia Geiger; Raoul Arnold Journal: Pediatr Radiol Date: 2016-12-13